IBRX earnings date and last-quarter result: last quarter miss, P/E -8.80. Updated 2026-07-23.
ImmunityBio (IBRX) Research Hub
ImmunityBio (IBRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 7.81 USD (-4.99%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.80, market cap 7.99B. This hub links to the full technical, earnings and options research available for IBRX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.81 USD (-4.99%) |
| 52-week range | 6.65 USD – 10.81 USD |
| Trend regime | Range |
| 14-day RSI | 29.7 (Oversold) |
| Trailing P/E | -8.80 |
| Market cap | 7.99B |
| Dividend yield | 0.00% |
Available research for IBRX
Covered Call on IBRX: how it works, illustrative setup around the real 7.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IBRX: how it works, illustrative setup around the real 7.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IBRX: how it works, illustrative setup around the real 7.81 USD price, max profit/loss, breakeven and when to use it. Educational.
IBRX technical analysis: range, last 7.81 USD, RSI 29.7, 52w range 6.65 USD–10.81 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is IBRX in?
ImmunityBio (IBRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is IBRX in an uptrend or downtrend?
As of 2026-10-26, IBRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IBRX's trailing P/E ratio?
IBRX's trailing P/E is -8.80, with a market cap of 7.99B. See the earnings research page for full valuation detail.